News | Radiopharmaceuticals and Tracers | September 17, 2015

Novation Presents at National Meeting on Achieving Reliable Mo-99 Isotope Supplies

Event gathered international and domestic policy and technical experts to discuss progress on domestic production of valuable radioisotope without use of highly enriched uranium

Novation, Mo-99, NNSA 2015 meeting, reliable supplies, domestic production

September 17, 2015 — At the National Nuclear Security Administration’s (NNSA) 2015 Mo-99 Topical Meeting, Novation offered its support of efforts to encourage the adoption of processes to create a reliable domestic supply of non-highly enriched uranium (HEU) molybdenum-99 (Mo-99).

The meeting, hosted by Argonne National Laboratory and held in Boston Aug. 31-Sept. 3, brought together international and domestic policy and technical experts to present and discuss progress toward achieving the production of Mo-99 without the use of HEU.

When it comes to determining how the heart is functioning or whether cancer is present, doctors and patients rely on diagnostic tests using a radioactive medical-grade isotope made from Mo-99. Mo-99 is historically produced using HEU, an extremely dangerous substance used in nuclear weapons.

Leah Gannon, MBA, radiopharmaceutical portfolio executive for Novation, represented the company at the meeting. “Radiopharmaceuticals play a key role in the diagnosis of various disease states and have a complex and fragile supply chain. It was an honor to participate in the topical meeting to provide information around the barriers to entry in implementing non-HEU Mo-99 into the healthcare supply chain and propose an action plan to overcome those barriers,” said Gannon.

In her role at Novation, Gannon has worked on numerous imaging initiatives with a specific emphasis on radiopharmaceutical distribution and contrast media utilization. She also works with multidisciplinary provider councils and task forces and is an active member of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) and the Association for Medical Imaging Management (AHRA).

Novation is committed to helping with the non-proliferation of HEU use in the production of radiopharmaceuticals as well as to helping the provider members it serves manage appropriate use of these medical isotopes. The company’s efforts include sharing best practices, providing active assistance with the development of successful programs, educating members on key medical imaging topics, and using institutional data to drive appropriate change in practice.

For more information: www.novationco.com

Related Content

CORAR Supports Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2018
News | Radiopharmaceuticals and Tracers | October 12, 2018
October 12, 2018 — The Council on Radionuclides and Radiopharmaceuticals Inc.
Huntsman Cancer Institute Installs First Preclinical nanoScan 3T PET/MRI in U.S.
News | PET-MRI | October 10, 2018
The Center for Quantitative Cancer Imaging at Huntsman Cancer Institute (HCI) at the University of Utah in Salt Lake...
Technology and Radionucleotide Development Will Fuel Mobile Gamma Camera Adoption
News | Nuclear Imaging | September 27, 2018
Advancements in healthcare technology, particularly in the surgery category, have led to an increasing adoption of...
Bruker Introduces New High-Performance Preclinical PET/CT Si78 System
Technology | PET-CT | September 26, 2018
September 26, 2018 — Bruker recently announced the introduction of the new preclinical...
Lightvision near-infrared fluorescence imaging system
News | Women's Health | September 11, 2018
Shimadzu Corp.
The Siemens Biograph Vision PET-CT system was released in mid-2018.

The Siemens Biograph Vision PET-CT system was released in mid-2018.

Feature | Nuclear Imaging | September 07, 2018 | By Dave Fornell
Nuclear imaging technology for both single photon emission computed tomography (SPECT) and positron emission tomography...
PET Imaging Agent Predicts Brain Tau Pathology, Alzheimer's Diagnosis
News | PET Imaging | September 05, 2018
Eli Lilly and Co. and Avid Radiopharmaceuticals Inc. announced a Phase 3 study of positron emission tomography (PET)...
Brain Study of 62,454 Scans Identifies Drives of Brain Aging
News | SPECT Imaging | August 27, 2018
In the largest known brain imaging study, scientists from five institutions evaluated 62,454 brain single photon...
Abnormal Protein Concentrations Found in Brains of Military Personnel With Suspected CTE

Researchers are using the tracer, which is injected into a patient, then seen with a PET scan, to see if it is possible to diagnose chronic traumatic encephalopathy in living patients. In this image, warmer colors indicate a higher concentration of the tracer, which binds to abnormal proteins in the brain. Credit UCLA Health.

News | PET Imaging | August 24, 2018
August 24, 2018 — In a small study of
PET Tracer Identifies Estrogen Receptor Expression Differences in Breast Cancer Patients
News | PET Imaging | August 09, 2018
In metastatic breast cancer, prognosis and treatment is largely influenced by estrogen receptor (ER) expression of the...